effects of deprenyl or propargylamine compounds and novel compositions comprising at least one mao inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs , steroids , acetaminophen , 5 - lipoxygenase inhibitors , leukotriene receptor antagonists , leukotriene a4 hydrolase inhibitors , antihistaminics , histamine 2 receptor antagonists , phosphodiesterase - 4 antagonists , cytokine antagonists , cd44 antagonists , antineoplastic agents , 3 - hydroxy - 3 - methylglutaryl coenzyme a inhibitors , estrogens , androgens , antiplatelet agents , antidepressants , helicobacter pylori inhibitors , proton pump inhibitors , thiazolidinediones , dual - action compounds , combinations of these drugs with other agents , derivatives and metabolites of synthetic and natural antiinflammatory agents . the compounds and compositions protect against gastrointestinal , renal and other toxicities induced by antiinflammatory agents , and enhance the beneficial effects of these drugs . effects of mao inhibitors such as 1 - deprenyl co - administered with antiinflammatory drugs or chemically attached to antniinflammatory drugs are disclosed . therapeutic methods of using mao inhibitors and antiinflammatory drugs for the prevention and treatment of inflammatory disorders , pain , fever , cancer , gastrointestinal lesions , and a variety of cardiac , cerebral and peripheral disorders are disclosed .